BioSpace News Archive

CTI BioPharma Corp. (Nasdaq: CTIC) today announced that the management team will present a corporate overview at the 43rd Annual Cowen Health Care Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET (7:30 a.m. PT).

Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) today announced that it will report financial results for the fourth quarter and year-end 2022 ending December 31st, 2022, on Wednesday, March 8, 2023, after the close of the US market.

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2022 and provided a summary of recent corporate highlights.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that its CEO and Chairman, Arun Menawat, will present an update on the Company’s business at the 43rd Annual Cowen Health Care Conference on Wednesday, March 8, 2023 at 9:10 a.m. Eastern Time.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2022.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Avidity management will be participating at the following conference.

Invitae, a leading medical genetics company, announced that Ken Knight, president and chief executive officer, will participate in a fireside chat at the TD Cowen 43rd Annual Health Care Conference on Monday, March 6, at 1:30 p.m. Eastern.

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2022.

Certara, Inc., announced that John Gallagher will succeed Andrew Schemick as Chief Financial Officer, effective April 1, 2023.

ImmunoGen, Inc. announced that on February 28, 2023, the Compensation Committee of the Company’s Board of Directors approved, in aggregate, grants of non-qualified stock option awards to purchase 49,450 shares of its common stock and restricted stock units covering 15,200 shares of its common stock to three new employees under the ImmunoGen, Inc.